StemVax features a recently approved US patent (US9764014B2) in the category of "Cancer Antigens" related to the "treatment of cancer using vaccination therapy." In January 2024, NovAccess announced $10.7 million financing to establish a strong financial base to advance development of novel cancer immunotherapies. The company positions itself in an underserved market with limited existing immunotherapy treatments for brain tumors.
Cyborg Score Rationale
NovAccess operates in an attractive therapeutic area (brain cancer immunotherapies) with granted patents and FDA Orphan Drug designation. However, the company is early-stage with minimal employee count (2-10), trades on OTC Pink/OTCQB indicating limited liquidity, and has not yet initiated human clinical trials as of the available data.
Top Insights
Operates in narrow niche of brain tumor immunotherapy where no FDA-approved immunotherapies currently exist
Secured $10.7M financing (January 2024) with strategic partner Sumner Global to advance clinical development
Platform centered on dendritic cell-based cancer vaccines with strong IP protection and Orphan Drug designation for TRL-AD1 candidate (2022)
Management team includes neuroscience experts from Cedars-Sinai and prior biotech founders, but company remains micro-cap with minimal workforce
Named Competitors
Keytruda (pembrolizumab) — Checkpoint inhibitor immunotherapy for multiple cancer types